Pre-order Enquiry
Request Free Sample
Global Cytokine Market - Segmented by Cytokine type and by Therapeutic Application - Growth, Trends, and Forecast (2022 - 2030)
SKU ID : INH-13103561 | Publishing Date : 01-Mar-2018 | No. of pages : 110
Request Sample
Request Customization
Check Discounts
The Cytokine Market is expected to witness a CAGR of 7.9% during the forecast period. North America dominate the global market due to the increasing prevalence of cancer in that region.
Increased Acceptance in Cancer Therapy
Cytokines are critical for tumor immune surveillance, and have demonstrated therapeutic anti-tumor activity in murine models and in the clinical treatment of several human cancers. To date, two cytokines have FDA approval as single agents for cancer treatment: high-dose, bolus IL-2 for metastatic melanoma and renal cell carcinoma and IFN-α for the adjuvant therapy of Stage III melanoma. So, increased acceptance in cancer therapy is driving market of Global Cytokine Market. Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Mesenchymal stem cells (MSCs) have emerged as major new cell technology, with a diverse spectrum of potential clinical applications. So, its potential contribution in stem cell therapy is also driving the Global Cytokine Market.
Additionally, potential biomarker for neonatal sepsis is also contributing towards the growth of Global cytokine market.
Short Half-Lives of Drug
Cytokines have inherently short half-life, which necessitates prolonged administration of cytokine therapies. This is a major problem in maintaining an effective dose over a long period. This becomes an even greater issue when cytokine is administered systematically. The short half-life of cytokines, the production of cytokines by cells in peripheral blood preparations, and the potential degradation make the stability, treatment, and storage of biological samples important factors in circulating cytokine measurement, analysis, and interpretation.
Additionally, lacks of specificity in cytokines is also restraining the growth of Global Cytokine Market.
North America is dominating the market
North America is dominating the cytokine market due to the rising prevalence of cancer in that region. Numerous animal tumor model studies have demonstrated that cytokines have broad anti-tumor activity and this has been translated into a number of cytokine-based approaches for cancer therapy. As per the Cancer Statistics in 2016, an estimated 1.6 million new cases of cancer were diagnosed in the United States, with prevalence expected to rise to almost 19 million by 2024. Augmenting growth in the R&D of cancer therapy, along with lesser side effects (as compared to chemotherapy) have predisposed cytokine therapy, which is a non-specific immunotherapy. This factor has increased the market share of cytokines, among cancer therapies in the United States.
Key Developments in the Market
• October 2017: Janssen announced US FDA approval of Stelara (ustekinumab) for the treatment of adolescents with moderate-to-severe plaque psoriasis
• September 2017: Bayer received FDA approval for Copanlisib in adults for relapsed follicular lymphoma, under the brand name ‘Aliqopa’
• September 2017: Roche received European approval for Actemra/RoActemra for the treatment of giant cell arteritis
Major Players: GLAXOSMITHKLINE, NOVARTIS INTERNATIONAL AG, ROCHE HOLDING AG, PFIZER INC., SANOFI SA, BAYER HEALTHCARE, THERMO FISHER SCIENTIFIC, BIOCON LIMITED, BIO-TECHNE CORPORATION, ABBVIE INC and JOHNSON & JOHNSON, among others.
Reasons to Purchase this Report
• Current and future cytokine market outlook in the developed and emerging markets
• Analyze various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet in excel
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs
Increased Acceptance in Cancer Therapy
Cytokines are critical for tumor immune surveillance, and have demonstrated therapeutic anti-tumor activity in murine models and in the clinical treatment of several human cancers. To date, two cytokines have FDA approval as single agents for cancer treatment: high-dose, bolus IL-2 for metastatic melanoma and renal cell carcinoma and IFN-α for the adjuvant therapy of Stage III melanoma. So, increased acceptance in cancer therapy is driving market of Global Cytokine Market. Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Mesenchymal stem cells (MSCs) have emerged as major new cell technology, with a diverse spectrum of potential clinical applications. So, its potential contribution in stem cell therapy is also driving the Global Cytokine Market.
Additionally, potential biomarker for neonatal sepsis is also contributing towards the growth of Global cytokine market.
Short Half-Lives of Drug
Cytokines have inherently short half-life, which necessitates prolonged administration of cytokine therapies. This is a major problem in maintaining an effective dose over a long period. This becomes an even greater issue when cytokine is administered systematically. The short half-life of cytokines, the production of cytokines by cells in peripheral blood preparations, and the potential degradation make the stability, treatment, and storage of biological samples important factors in circulating cytokine measurement, analysis, and interpretation.
Additionally, lacks of specificity in cytokines is also restraining the growth of Global Cytokine Market.
North America is dominating the market
North America is dominating the cytokine market due to the rising prevalence of cancer in that region. Numerous animal tumor model studies have demonstrated that cytokines have broad anti-tumor activity and this has been translated into a number of cytokine-based approaches for cancer therapy. As per the Cancer Statistics in 2016, an estimated 1.6 million new cases of cancer were diagnosed in the United States, with prevalence expected to rise to almost 19 million by 2024. Augmenting growth in the R&D of cancer therapy, along with lesser side effects (as compared to chemotherapy) have predisposed cytokine therapy, which is a non-specific immunotherapy. This factor has increased the market share of cytokines, among cancer therapies in the United States.
Key Developments in the Market
• October 2017: Janssen announced US FDA approval of Stelara (ustekinumab) for the treatment of adolescents with moderate-to-severe plaque psoriasis
• September 2017: Bayer received FDA approval for Copanlisib in adults for relapsed follicular lymphoma, under the brand name ‘Aliqopa’
• September 2017: Roche received European approval for Actemra/RoActemra for the treatment of giant cell arteritis
Major Players: GLAXOSMITHKLINE, NOVARTIS INTERNATIONAL AG, ROCHE HOLDING AG, PFIZER INC., SANOFI SA, BAYER HEALTHCARE, THERMO FISHER SCIENTIFIC, BIOCON LIMITED, BIO-TECHNE CORPORATION, ABBVIE INC and JOHNSON & JOHNSON, among others.
Reasons to Purchase this Report
• Current and future cytokine market outlook in the developed and emerging markets
• Analyze various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet in excel
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
